# A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

> **NCT05546151** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 24 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** BMS-986322
- **OTHER:** Placebo for BMS-986322

## Key facts

- **NCT ID:** NCT05546151
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-28
- **Primary completion:** 2023-04-07
- **Final completion:** 2023-04-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546151, "A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05546151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*